Scandion Oncology A/S   Report issue

For profit Phase 2
Founded: Copenhagen Denmark (2017)

Organization Overview

First Clinical Trial
2020
NCT04247256
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Scandion Oncology A/S

Active Ingredients

Drugs in Phase 2 Trials (3)

gemcitabine (gemzar) (1 trial)

paclitaxel (taxol) (1 trial)

sco-101 (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenocarcinoma (Phase 2)

Colorectal Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 3